Oculis Secures FDA SPA Agreement for Optic Neuritis Trial
Event summary
- Oculis received FDA SPA agreement for PIONEER-1 trial of Privosegtor in optic neuritis (ON).
- PIONEER-1 is the first registrational trial in the PIONEER program, with primary endpoint of 15-letter gain in low-contrast visual acuity (LCVA) at Month 3.
- Privosegtor has Breakthrough Therapy designation from FDA and PRIME designation from EMA for ON.
- The trial will enroll patients with and without multiple sclerosis (MS), with 12-month follow-up for safety and tolerability.
The big picture
Oculis' SPA agreement with the FDA for the PIONEER-1 trial of Privosegtor in optic neuritis represents a significant regulatory milestone. The agreement validates the trial design and endpoints, providing a clear path to a potential NDA submission. This aligns with broader industry trends toward neuroprotective therapies in ophthalmology, addressing a critical unmet need in optic neuropathies. The potential $7 billion U.S. market for acute optic neuropathies underscores the strategic importance of this development.
What we're watching
- Regulatory Clarity
- Whether the SPA agreement will accelerate Privosegtor's path to NDA submission and approval.
- Clinical Execution
- The pace at which Oculis can enroll and complete the PIONEER-1 trial, given the broad patient population.
- Market Potential
- How Privosegtor's success in ON could expand its applicability to other neuro-ophthalmic and neurological indications.
Related topics